Have a feature idea you'd love to see implemented?
Let us know!
CSBR Champions Oncology Inc
Price (delayed)
$4.27
Market cap
$58.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.25
Enterprise value
$62.26M
Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based
Highlights
The net income has soared by 55% YoY and by 53% from the previous quarter
The company's EPS has surged by 55% YoY and by 54% QoQ
Champions Oncology's equity has shrunk by 117% YoY but it has surged by 83% QoQ
CSBR's quick ratio is up by 11% since the previous quarter but it is down by 9% year-on-year
Key stats
What are the main financial stats of CSBR
Market
Valuations
Earnings
Shares outstanding
13.59M
Market cap
$58.05M
Enterprise value
$62.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.21
Revenue
$51.66M
EBIT
-$3.44M
EBITDA
-$1.56M
Free cash flow
-$2M
Per share
Balance sheet
Liquidity
EPS
-$0.25
Free cash flow per share
-$0.15
Book value per share
-$0.02
Revenue per share
$3.8
TBVPS
$1.81
Total assets
$24.93M
Total liabilities
$25.27M
Debt
$7.11M
Equity
-$332,000
Working capital
-$5.99M
Debt to equity
-21.41
Current ratio
0.69
Quick ratio
0.62
Net debt/EBITDA
-2.7
Margins
Efficiency
Dividend
EBITDA margin
-3%
Gross margin
44.3%
Net margin
-6.6%
Operating margin
-6.7%
Return on assets
-12.8%
Return on equity
N/A
Return on invested capital
-38.1%
Return on capital employed
-59.5%
Return on sales
-6.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CSBR stock price
How has the Champions Oncology stock price performed over time
Intraday
-1.16%
1 week
-4.26%
1 month
-5.11%
1 year
-20.34%
YTD
-24.02%
QTD
-12.32%
Financial performance
How have Champions Oncology's revenue and profit performed over time
Revenue
$51.66M
Gross profit
$22.87M
Operating income
-$3.47M
Net income
-$3.4M
Gross margin
44.3%
Net margin
-6.6%
The net income has soared by 55% YoY and by 53% from the previous quarter
The company's operating income has surged by 54% YoY and by 53% QoQ
The operating margin has soared by 54% from the previous quarter and by 53% YoY
The net margin has soared by 54% QoQ and by 54% YoY
Growth
What is Champions Oncology's growth rate over time
Valuation
What is Champions Oncology stock price valuation
P/E
N/A
P/B
N/A
P/S
1.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.21
The company's EPS has surged by 55% YoY and by 54% QoQ
Champions Oncology's equity has shrunk by 117% YoY but it has surged by 83% QoQ
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 2.3 and 20% lower than the last 4 quarters average of 1.4
The revenue has grown by 3% from the previous quarter
Efficiency
How efficient is Champions Oncology business performance
The company's return on sales has surged by 55% QoQ and by 54% YoY
The ROA has soared by 51% from the previous quarter and by 42% YoY
The company's return on invested capital rose by 49% QoQ and by 35% YoY
Dividends
What is CSBR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CSBR.
Financial health
How did Champions Oncology financials performed over time
The total assets has declined by 17% year-on-year and by 4.6% since the previous quarter
CSBR's quick ratio is up by 11% since the previous quarter but it is down by 9% year-on-year
Champions Oncology's equity has shrunk by 117% YoY but it has surged by 83% QoQ
The debt fell by 15% YoY and by 4.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.